Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.39 |
| ▸ | DRD3 | P35462 | 14/20 | 0.38 |
| ▸ | HTR1A | P08908 | 7/20 | 0.36 |
| ▸ | DRD1 | P21728 | 7/20 | 0.36 |
| ▸ | DRD4 | P21917 | 7/20 | 0.36 |
| ▸ | DRD5 | P21918 | 7/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL614061 | 1.00 | DRD2 (0.39) | DRD2DRD3HTR1ADRD1DRD4 | |
| SCHEMBL613674 | 1.00 | DRD2 (0.39) | DRD2DRD3HTR1ADRD1DRD4 | |
| SCHEMBL614174 | 0.87 | ESR1 (0.38) | DRD2 | |
| SCHEMBL614173 | 0.87 | ESR1 (0.38) | DRD2 | |
| SCHEMBL614595 | 0.81 | ALDH1A1 (0.38) | DRD2DRD3 | |
| SCHEMBL614972 | 0.81 | ALDH1A1 (0.38) | DRD2DRD3 | |
| SCHEMBL614596 | 0.81 | ALDH1A1 (0.38) | DRD2DRD3 | |
| SCHEMBL15809628 | 0.81 | HTR1A (0.35) | DRD2HTR1ADRD1 | |
| SCHEMBL614735 | 0.73 | PIK3CD (0.42) | — | |
| SCHEMBL29429338 | 0.73 | PIK3CD (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016102400-A1 | COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND AND A SPECIFIC SOLVENT | L'OREAL (FR) | 2016-06-30 | — | — | WO | claimed |
| WO-2016102402-A1 | AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND, A C2-C4 MONOALCOHOL, AND A GLYCOL | L'OREAL (FR) | 2016-06-30 | — | — | WO | claimed |
| WO-2016102399-A1 | AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND AND A HYDROTROPE | L'OREAL (FR) | 2016-06-30 | — | — | WO | claimed |
| WO-2016102398-A1 | AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND, A POLYMER AND A GLYCOL | L'OREAL (FR) | 2016-06-30 | — | — | WO | claimed |
| EP-2529735-B1 | COMPOSITIONS COMPRISING 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL DERIVATIVES WITH TYROSINASE ENZYME INHIBITING ACTIVITY | GALDERMA RES & DEV (FR) | 2014-06-25 | — | — | EP | claimed |
| US-8372879-B2 | 4-(heterocycloalkyl) benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-02-12 | — | — | US | claimed |
| EP-2529735-A1 | Novel 4-(heterocycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics | Galderma Research & Development (FR) | 2012-12-05 | — | — | EP | claimed |
| EP-2373310-B1 | NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS | GALDERMA RES & DEV (FR) | 2012-10-10 | — | — | EP | claimed |
| US-20120041213-A1 | 4-(HETEROCYCLOALKYL) BENZENE -1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-02-16 | — | — | US | claimed |
| EP-2373310-A1 | NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS | Galderma Research & Development (FR) | 2011-10-12 | — | — | EP | claimed |
| WO-2010063773-A1 | NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-06-10 | — | — | WO | claimed |
| WO-2016102400-A1 | COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND AND A SPECIFIC SOLVENT | L'OREAL (FR) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016102402-A1 | AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND, A C2-C4 MONOALCOHOL, AND A GLYCOL | L'OREAL (FR) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016102399-A1 | AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND AND A HYDROTROPE | L'OREAL (FR) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016102398-A1 | AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND, A POLYMER AND A GLYCOL | L'OREAL (FR) | 2016-06-30 | — | — | WO | disclosed |
| EP-2529735-A1 | Novel 4-(heterocycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics | Galderma Research & Development (FR) | 2012-12-05 | — | — | EP | disclosed |
| EP-2373310-B1 | NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS | GALDERMA RES & DEV (FR) | 2012-10-10 | — | — | EP | disclosed |
| US-20120041213-A1 | 4-(HETEROCYCLOALKYL) BENZENE -1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-02-16 | — | — | US | disclosed |
| EP-2373310-A1 | NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS | Galderma Research & Development (FR) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010063773-A1 | NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041213-A1 | 4-(HETEROCYCLOALKYL) BENZENE -1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS | TYR, DDT, PAH | DRD2 1041/4885DRD3 633/4885HTR1A 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.